



Texas Center for Proton Therapy treats first patient with isocentric Cone Beam CT and Pencil Beam Scanning

Dallas area facility represents the leading edge of precision proton therapy treatment.

Dallas-Fort Worth, TX, April 19, 2016 – Texas Center for Proton Therapy and IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions for the treatment of cancer, announce the first patient treated in North America with the center’s high-precision tandem of isocentric Cone Beam CT (CBCT) guidance and pencil beam scanning in a 360° Proteus®PLUS gantry.

Pencil beam scanning radiates tumors with an ultra-fine proton beam that requires precise positioning of the patient to ensure treatment accuracy. IBA’s ProteusPLUS 360° gantry allows the acquisition of CBCT volumetric imaging at isocenter to assure precise patient positioning that effectively leverages the power of pencil beam scanning to provide the most accurate proton therapy treatment available. This unique combination of technologies allows Texas Center for Proton Therapy to provide treatment for indications demanding the utmost precision, while leading the way to adaptive proton therapy and improved patient outcomes.

The multi-room ProteusPLUS installation at the Texas Center for Proton Therapy has been in clinical operation since November 2015 and represents the fastest ramp-up from ground-breaking to robust patient treatment volumes. The skilled center staff, combining more than 75 years of cumulative proton experience, has created a workflow that optimizes efficiency and patient comfort, while delivering outstanding clinical care with the most reliable equipment on the market.

Dr. Andrew K. Lee, M.D., M.P.H., Medical Director at Texas Center for Proton Therapy, commented:
“The combination of volumetric CBCT image guidance and pencil beam scanning begins a new era in proton therapy. This will allow proton therapy to help a wider range of cancer patients while improving the treatment for currently treated indications. This vital technology will help fulfill our joint mission to protect, enhance, and save lives.”

Beth Klein, President of IBA Proton Therapy North America, added:
“The Texas Center for Proton Therapy has implemented a powerful clinical tool in the fight against cancer and IBA is a proud partner in their effort to deliver advanced Proton Therapy treatment and improve the quality of life for cancer patients and their families in the Dallas-Fort Worth area.”

About Proton Therapy

Proton Therapy is a highly precise, targeted cancer radiotherapy treatment. Compared to photons, protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. This technique offers cancer centers the opportunity to develop new protocols delivering higher doses to the tumor aiming at improved outcome for equal risk of side-effects, or keeping the same dose but targeting improved patient’s quality of life. Today, more than half of all proton therapy clinical facilities worldwide



are equipped with IBA systems. This includes 20 proton therapy centers currently in operation and 18 additional centers under development.

While proton therapy today represents less than 1% of radiotherapy treatments, studies estimate that more than 20% of patients treated by radiotherapy would benefit from being treated by this technique.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1200 people worldwide, IBA has installed systems across the world, from Europe and the US to emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

About Texas Center for Proton Therapy

Texas Center for Proton Therapy is the North Texas region's first proton therapy center. The center features latest-generation technology, including pencil-beam scanning and image-guided proton therapy, providing precise radiation treatment with the opportunity to reduce side effects. Texas Oncology and The US Oncology Network, supported by McKesson Specialty Health, and Baylor Health Enterprises, an affiliate of Baylor Health Care System, collaborated to develop the proton therapy facility in the Dallas-Fort Worth Metroplex. Opened in late 2015, the facility provides advanced cancer treatment through Texas Oncology, an independent oncology practice and pioneer of community-based cancer care. For more information, visit: www.TexasCenterforProtonTherapy.com or call 469-513-5500.